• Pharming AGM presentation flagged 2025 revenue of USD 376.1 million, adjusted operating profit of USD 36.4 million, operating cash flow of USD 54.7 million.
• 2026 guidance set at revenue of USD 405 million to USD 425 million, operating expenses of USD 330 million to USD 335 million.
• Shareholders to vote on adopting the 2025 financial statements, advisory vote on the 2025 remuneration report, discharge of directors.
• Ballots also cover external auditor appointment, changes to board remuneration policy, authority to issue shares or grant option rights.
• Additional vote seeks authorization for share repurchases, including the ability to restrict or exclude pre-emptive rights.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharming Group NV published the original content used to generate this news brief on May 28, 2026, and is solely responsible for the information contained therein.